Alpine Immune Sciences (ALPN) announced the appointment of Wolfgang Dummer to chief medical officer effective October 2. He succeeds Andrew Sandler, who will transition responsibilities to Dummer through the remainder of the year. He joins Alpine from Rigel Pharmaceuticals (RIGL), where he served as chief medical officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALPN:
- Alpine Immune Sciences price target raised to $22 from $14 at Oppenheimer
- Alpine Immune Sciences initiates second dosing cohort in RUBY-3 study
- Alpine Immune Sciences price target raised to $17 from $11 at H.C. Wainwright
- Alpine Immune Sciences reports Q2 EPS (27c), consensus (37c)
- Is ALPN a Buy, Before Earnings?